Levetiracetam 500mg/5ml Vial is an intravenous anticonvulsant medication primarily utilized as an alternative for patients with epilepsy when oral administration is not feasible. It is commonly prescribed to manage partial-onset, myoclonic, or primary generalized tonic-clonic seizures. The intravenous formulation is provided as a concentrate that must be diluted prior to administration.
Administration Overview
-
Preparation: The concentrate must be diluted in a compatible intravenous diluent before use.
-
Compatible Diluents: Options include 0.9% Sodium Chloride (Normal Saline), Lactated Ringer's injection, or 5% Dextrose (D5W).
-
Infusion Rate: Administered as a slow intravenous infusion over a defined timeframe as directed by clinical protocols. Rapid pushing is avoided.
-
Maintenance Therapy: Treatment is individualized based on patient response and clinical assessment. Adjustments are managed under medical supervision.
Renal Considerations
Because levetiracetam is cleared by the kidneys, patients with renal impairment require careful evaluation and individualized dosage adjustments determined by a healthcare professional based on renal function testing.
Important Precautions
-
Psychiatric Monitoring: Healthcare professionals must monitor patients closely for mood shifts, irritability, depression, anxiety, or suicidal ideation.
-
Abrupt Discontinuation: Do not stop the medication abruptly unless required by severe systemic adverse reactions; sudden cessation can trigger potential seizure recurrence.
-
Sedation Risks: Concurrent use with central nervous system depressants like opioid analgesics increases the risk of severe drowsiness and sedation.
